The MarketWatch News Department was not involved in the creation of this content. Vyome's offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 ...
Enphase Energy (ENPH) may be undervalued despite near-term headwinds—see key catalysts, new products, and why a rebound could ...
A big part of WeWork's pitch to potential investors in its IPO is that it has a huge opportunity ahead. Experts say its much smaller than WeWork says.
Hosted on MSN
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations
The company expects top line data from the PIK3CA mutant cohort of the VIKTORIA-1 trial in late Q1 or Q2 2026. Sullivan stated, "We expect to complete the submission [to FDA] this quarter." The ...
Autodesk's AI-driven Project Bernini expands the addressable market and reduces cyclicality. Find out more about ADSK stock ...
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity Vyome’s offering is a first-of-its-kind in a broader $20B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback